Vaxcyte, Inc. (NASDAQ:PCVX) Stock Position Raised by Crestline Management LP

Crestline Management LP lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 88.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 101,035 shares of the company’s stock after buying an additional 47,452 shares during the quarter. Crestline Management LP owned about 0.08% of Vaxcyte worth $8,271,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brevan Howard Capital Management LP lifted its stake in shares of Vaxcyte by 137.8% in the 4th quarter. Brevan Howard Capital Management LP now owns 4,393 shares of the company’s stock valued at $360,000 after purchasing an additional 2,546 shares during the last quarter. Bridgefront Capital LLC grew its stake in Vaxcyte by 4.2% in the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company’s stock valued at $347,000 after buying an additional 172 shares during the last quarter. Brown Advisory Inc. raised its holdings in Vaxcyte by 25.3% in the 4th quarter. Brown Advisory Inc. now owns 556,209 shares of the company’s stock worth $45,531,000 after acquiring an additional 112,170 shares during the period. Bayesian Capital Management LP bought a new stake in Vaxcyte during the fourth quarter valued at about $1,654,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Vaxcyte in the fourth quarter worth about $7,471,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Vaxcyte stock opened at $34.28 on Tuesday. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06. The stock has a fifty day moving average price of $50.03 and a two-hundred day moving average price of $76.51. The firm has a market capitalization of $4.42 billion, a P/E ratio of -7.45 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several research analyst reports. Evercore ISI upgraded shares of Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Guggenheim reissued a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. The Goldman Sachs Group reduced their price objective on Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, Bank of America reduced their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.